Tandem Diabetes Care Inc (BSP:T2ND34)
R$ 5.8 -0.38 (-6.15%) Market Cap: 397.47 Mil Enterprise Value: 1.23 Bil PE Ratio: 0 PB Ratio: 8.86 GF Score: 45/100

Tandem Diabetes Care Inc at Goldman Sachs Healthcare Conference Transcript

Jun 08, 2026 / 07:20PM GMT
Release Date Price: R$6.4 (-5.60%)
David Roman
Goldman Sachs & Company, Inc. - Analyst

Next presentation. Very pleased to welcome John Sheridan, President and CEO of Tandem and Leigh Vosseller, Executive Vice President and CFO.

Questions & Answers

David Roman
Goldman Sachs & Company, Inc. - Analyst

Very timely to have you here coming off ADA. So I thought that maybe that would be a good place to start just to talk us through kind of your reflections on the conference, key themes, both from kind of a market perspective, what you heard kind of walking the floor and talking to customers and what you thought the big takeaways for Tandem were?

John Sheridan
Tandem Diabetes Care Inc - President, Chief Executive Officer, Director

Yes. It was a great conference for us. We had -- you guys probably know we received CE Mark for our pregnancy indication just a few days before the conference started. And we had a symposium on Saturday morning in which we actually went through and presented the data to a pretty large group of doctors, and that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot